ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat
CBP74003
| I. Background | |
|
抗体依赖的细胞介导的细胞毒性作用（ADCC，antibody-dependent cell-mediated cytotoxicity ）是指抗体的 Fab 段结合病毒感染的细胞或肿瘤细胞的抗原表位，其 Fc 段与杀 伤细胞（NK 细胞、巨噬细胞等）表面的 FcR 结合，介导杀伤细胞直接杀伤靶细胞，它是 抗肿瘤的治疗性抗体药物发生作用的一种作用重要机制。 传统用于测定 ADCC/ADCP 的方法主要依赖于相关原代免疫细胞的分离、体外分化， 进而测量靶细胞的杀伤或吞噬效应。这些方法高度依赖供体原代细胞，价格昂贵且费时费 力，对原代细胞的分离分化过程对实验操作的要求非常高，实验失败风险较大，由于分离 分化细胞纯度问题，还存在检测信号低以及不稳定均一的问题。另外，原代细胞具有不可 再生性，每次实验的细胞供体来源可能都不一致，实验结果可重复性较差，可能存在批次 差异。由于以上这些因素的影响，在需要高质量控制的药物开发过程中，很难建立稳定可 靠的检测方法。 |
|
| II. Description | |
|
ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT Jurkat 报告基因药靶模 型很好的模拟了体内 ADCC 的信号转导过程，原理见下图所示。
|
|
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-CD16(V158) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+300μg/ml hygromycin+1μg/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Immediately upon receipt, store in liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Recombinant ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat stably expressing CD16a（V158）.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell (High Affinity)-Fcγ-NFAT Jurkat cell（C36）. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cells(Suspended,C5).
Figure 4. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cell (Adherent,C12).
